At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
Talazoparibdrug
Likely dose
Talazoparib 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open-label Study Of 14c-labeled Talazoparib In Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Talazoparib for Advanced Solid Tumors. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesHungary
CollaboratorsMedivation, Inc.
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedMar 2017
Primary CompletionJun 2017
TodayJul 2026
First PostedMar 3, 2017
Enrollment StartSep 1, 2016
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.3 years ago
Interventions
Talazoparibdrug
1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib